Janet S Hildebrand1, Kristin Wallace2, Whitney S Graybill3, Linda E Kelemen4. 1. Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, 29425, United States. Electronic address: hildebja@musc.edu. 2. Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, 29425, United States; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, United States. Electronic address: wallack@musc.edu. 3. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, United States; Department of Obstetrics and Gynecology, College of Medicine, Medical University of South Carolina, Charleston, SC, 29425, United States. Electronic address: graybill@musc.edu. 4. Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, 29425, United States; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, United States. Electronic address: kelemen@musc.edu.
Abstract
BACKGROUND: Black women with ovarian cancer in the U.S. have lower survival than whites. We aimed to identify factors associated with racial differences in ovarian cancer treatment and overall survival (OS). METHODS: We examined data from 365 white and 95 black ovarian cancer patients from the Hollings Cancer Center Cancer Registry in Charleston, S.C. between 2000 and 2015. We used unconditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) between race and receipt of surgery and chemotherapy, and Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% CIs between race and OS. Model variables included diagnosis center, stage, histology, insurance status, smoking, age-adjusted Charlson comorbidity index (AACI) and residual disease. Interactions between race and AACI were assessed using -2 log likelihood tests. RESULTS: Blacks vs. whites were over two-fold less likely to receive a surgery-chemotherapy sequence (multivariable-adjusted OR 2.46, 95% CI 1.43-4.21), particularly if they had a higher AACI (interaction p = 0.008). In multivariable-adjusted Cox models, black women were at higher risk of death (HR 1.81, 95% CI 1.35-2.43) than whites, even when restricted to patients who received a surgery-chemotherapy sequence (HR 1.79, 95% CI 1.10-2.89) and particularly for those with higher AACI (HR 4.70, 95% CI 2.00 - 11.02, interaction p = 0.01). CONCLUSIONS: Among blacks, higher comorbidity associates with less chance of receiving guideline-based treatment and also modifies OS. Differences in receipt of guideline-based care do not completely explain survival differences between blacks and whites with ovarian cancer. These results highlight opportunities for further research.
BACKGROUND: Black women with ovarian cancer in the U.S. have lower survival than whites. We aimed to identify factors associated with racial differences in ovarian cancer treatment and overall survival (OS). METHODS: We examined data from 365 white and 95 black ovarian cancerpatients from the Hollings Cancer Center Cancer Registry in Charleston, S.C. between 2000 and 2015. We used unconditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) between race and receipt of surgery and chemotherapy, and Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% CIs between race and OS. Model variables included diagnosis center, stage, histology, insurance status, smoking, age-adjusted Charlson comorbidity index (AACI) and residual disease. Interactions between race and AACI were assessed using -2 log likelihood tests. RESULTS: Blacks vs. whites were over two-fold less likely to receive a surgery-chemotherapy sequence (multivariable-adjusted OR 2.46, 95% CI 1.43-4.21), particularly if they had a higher AACI (interaction p = 0.008). In multivariable-adjusted Cox models, black women were at higher risk of death (HR 1.81, 95% CI 1.35-2.43) than whites, even when restricted to patients who received a surgery-chemotherapy sequence (HR 1.79, 95% CI 1.10-2.89) and particularly for those with higher AACI (HR 4.70, 95% CI 2.00 - 11.02, interaction p = 0.01). CONCLUSIONS: Among blacks, higher comorbidity associates with less chance of receiving guideline-based treatment and also modifies OS. Differences in receipt of guideline-based care do not completely explain survival differences between blacks and whites with ovarian cancer. These results highlight opportunities for further research.
Authors: Ryan J Ellis; Cary Jo R Schlick; Joe Feinglass; Mary F Mulcahy; Al B Benson; Sheetal M Kircher; Tony D Yang; David D Odell; Karl Bilimoria; Ryan P Merkow Journal: BMJ Qual Saf Date: 2019-07-31 Impact factor: 7.035
Authors: Holly R Harris; Kristin A Guertin; Tareq F Camacho; Courtney E Johnson; Anna H Wu; Patricia G Moorman; Evan Myers; Traci N Bethea; Elisa V Bandera; Charlotte E Joslin; Heather M Ochs-Balcom; Lauren C Peres; Will T Rosenow; Veronica W Setiawan; Alicia Beeghly-Fadiel; Lauren F Dempsey; Lynn Rosenberg; Joellen M Schildkraut Journal: Int J Cancer Date: 2022-06-30 Impact factor: 7.316
Authors: Lauren C Peres; Christelle Colin-Leitzinger; Sweta Sinha; Jeffrey R Marks; Jose R Conejo-Garcia; Anthony J Alberg; Elisa V Bandera; Andrew Berchuck; Melissa L Bondy; Brock C Christensen; Michele L Cote; Jennifer Anne Doherty; Patricia G Moorman; Edward S Peters; Carlos Moran Segura; Jonathan V Nguyen; Ann G Schwartz; Paul D Terry; Christopher M Wilson; Brooke L Fridley; Joellen M Schildkraut Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-05-04 Impact factor: 4.090
Authors: Tomi F Akinyemiju; Lauren E Wilson; Nicole Diaz; Anjali Gupta; Bin Huang; Maria Pisu; April Deveaux; Margaret Liang; Rebecca A Previs; Haley A Moss; Ashwini Joshi; Kevin C Ward; Maria J Schymura; Andrew Berchuck; Arnold L Potosky Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-07-01 Impact factor: 4.090
Authors: Ishleen Kaur; M N Doja; Tanvir Ahmad; Musheer Ahmad; Amir Hussain; Ahmed Nadeem; Ahmed A Abd El-Latif Journal: Comput Intell Neurosci Date: 2021-12-28
Authors: Sarah P Huepenbecker; Charlotte C Sun; Shuangshuang Fu; Hui Zhao; Kristin Primm; Sharon H Giordano; Larissa A Meyer Journal: Cancer Date: 2021-08-04 Impact factor: 6.860
Authors: Arnethea L Sutton; Ashley S Felix; Dipankar Bandyopadhyay; Reuben Retnam; William G Hundley; Vanessa B Sheppard Journal: Breast Cancer Res Treat Date: 2021-04-02 Impact factor: 4.624